We are live on ! Find out more
WST icon

West Pharmaceutical

250 hedge funds and large institutions have $4.71B invested in West Pharmaceutical in 2016 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 96 increasing their positions, 83 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

16% more capital invested

Capital invested by funds: $4.05B → $4.71B (+$663M)

16% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 83

12% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 26

1% more funds holding

Funds holding: 248250 (+2)

0.64% more ownership

Funds ownership: 93.49%94.13% (+0.64%)

Holders
250
Holders Change
+2
Holders Change %
+0.81%
% of All Funds
6.66%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.16%
New
29
Increased
96
Reduced
83
Closed
26
Calls
$1.28M
Puts
Net Calls
+$1.28M
Net Calls Change
-$1.15M
Name Holding Trade Value Shares
Change
Change in
Stake
RCG
26
Ruane, Cunniff & Goldfarb
New York
$37M -$27.6M -458,278 -46%
Renaissance Technologies
27
Renaissance Technologies
New York
$35.6M -$18.1K -300 -0.1%
Lord, Abbett & Co
28
Lord, Abbett & Co
New Jersey
$35.5M +$13.5M +224,991 +78%
Schroder Investment Management Group
29
Schroder Investment Management Group
United Kingdom
$34.8M -$3.23M -53,700 -10%
ICM
30
IronBridge Capital Management
Illinois
$32.2M +$706K +11,740 +3%
Bank of America
31
Bank of America
North Carolina
$29.4M -$1.34M -22,253 -5%
BIM
32
BlackRock Investment Management
Delaware
$29.2M +$705K +11,712 +3%
Dimensional Fund Advisors
33
Dimensional Fund Advisors
Texas
$28.9M -$8.94M -148,618 -26%
O
34
OppenheimerFunds
New York
$28.3M +$1.62M +26,858 +7%
Invesco
35
Invesco
Georgia
$28M -$9.26M -153,905 -28%
Macquarie Group
36
Macquarie Group
Australia
$27.6M +$3.85M +64,051 +19%
EVM
37
Eaton Vance Management
Massachusetts
$25.5M -$44.4K -738 -0.2%
DIA
38
Denver Investment Advisors
Colorado
$24.2M +$135K +2,238 +0.6%
CRCP
39
Copper Rock Capital Partners
Massachusetts
$23.5M -$83.6K -1,390 -0.4%
Ameriprise
40
Ameriprise
Minnesota
$22.2M +$1.15M +19,049 +6%
Wells Fargo
41
Wells Fargo
California
$22.1M -$2.37M -39,385 -11%
CWAM
42
Columbia Wanger Asset Management
Illinois
$22M +$19.1M +317,164 New
Charles Schwab
43
Charles Schwab
California
$21.5M +$441K +7,335 +2%
Public Employees Retirement Association of Colorado
44
Public Employees Retirement Association of Colorado
Colorado
$21.2M -$17.9K -297 -0.1%
KCM
45
Kennedy Capital Management
Missouri
$19.9M -$2.97M -49,286 -15%
Allianz Asset Management
46
Allianz Asset Management
Germany
$19.6M +$17M +283,241 New
CRC
47
Curi RMB Capital
Illinois
$18.5M -$4.7M -78,055 -23%
TCIM
48
TIAA CREF Investment Management
New York
$17.6M -$2.29M -37,988 -13%
Prudential Financial
49
Prudential Financial
New Jersey
$16.8M +$5.98M +99,400 +69%
BTW
50
Boston Trust Walden
Massachusetts
$16.7M -$5.02M -83,418 -26%

WST Hedge Fund Activity: Q1 2016 in Review

250 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q1 2016, worth a combined $4.71B — up 16% from $4.05B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new WST positions and 26 closed out — a net gain of 3 holders — while 96 added to existing stakes and 83 trimmed.

The largest buyer was Select Equity Group, adding an estimated $54.2M. The largest seller was Kalmar Investments, cutting an estimated $29.4M.

  • 250 institutional investors held West Pharmaceutical (WST) as of Q1 2016, up from 248 in Q4 2015.
  • Funds reported $4.71B of West Pharmaceutical stock for Q1 2016, up 16% quarter-over-quarter.
  • 29 funds opened new West Pharmaceutical positions in Q1 2016 and 26 closed out, a net change of +3 holders.
  • The largest West Pharmaceutical buyer in Q1 2016 was Select Equity Group, an estimated $54.2M added.
  • The largest West Pharmaceutical seller in Q1 2016 was Kalmar Investments, an estimated $29.4M sold.

Based on aggregated 13F filings for Q1 2016.